Get started
Author

Cameron Lilley

Observed names: C Lilley, C. Lilley, Lilley, Cameron
ORCID: 0000-0002-4647-6085
Observed ORCID: 0000-0002-4647-6085
OpenAlex ID: A5072094428
Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
2019 · Ash Bullement, Paul Nathan, et al. · PharmacoEconomics - Open · 25
PDF
Predicting overall survival in patients (pts) with treatment-naive metastatic Merkel cell carcinoma (mMCC) treated with avelumab.
2018 · Ash Bullement, Sandra P. D'Angelo, et al. · Journal of Clinical Oncology · 9
Cost-Effectiveness of Brentuximab Vedotin Versus Physician’s Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada
2023 · David Elsea, Kerry J. Savage, et al. · Advances in Therapy · 3
PDF
Cost–effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma
2021 · Tanja Podkonjak, Holly Cranmer, et al. · Journal of Comparative Effectiveness Research · 3
Psy167 - Comparison of Pharmacoeconomic (pe) Evaluations for Drugs for Rare Diseases (drds) Evaluated by Cadth and Nice.
2018 · S. Gosain, A. Bullement, et al. · Value in Health · 2
PDF
Mo2 - Modelling Overall Survival in Immunotherapy Using Parametric Techniques: Avelumab in Previously Treated Metastatic Merkel Cell Carcinoma
2018 · A. Bullement, A. Amin, et al. · Value in Health · 1
PDF
HTA143 Examining the Relationship Between the NICE WTP Threshold and the Severity Modifier
2025 · Simone Critchlow, Cameron Lilley, et al. · Value in Health
HTA336 The Value Flower in Bloom: Emerging Recognition of Uncaptured Benefits in NICE HTA Decisions
2025 · David Aitken, Simone Critchlow, et al. · Value in Health
HTA400 Price Visibility in Combination Medicines: A Review of Single Technology Appraisals by the National Institute for Health and Care Excellence (NICE) for Combination Medicines in Oncology
2024 · S Critchlow, C Lilley · Value in Health
HTA319 A 10-Year Review of the Willingness-to-Pay (WTP) Thresholds for Single Technology Appraisals From the National Institute for Health and Care Excellence (NICE)
2024 · S Critchlow, C Lilley · Value in Health
PDF
MSR61 Comparative Efficacy of Osilodrostat Versus Pasireotide Subcutaneous and Pasireotide Long-Acting Release for the Treatment of Cushing's Disease – A Patient-Level Data Indirect Treatment Comparison Using Propensity Score Weighting
2022 · E Tyas, A Piacentini, et al. · Value in Health
PDF
POSA221 5-Years On: Reflections on the Cancer Drugs Fund
2022 · S Critchlow, C Lilley · Value in Health
PNS132 Did the NICE Technical Engagement Process Deliver More Efficient Decision Making?
2020 · A.M. Barnes, T. Qu, et al. · Value in Health
Pcn380 a Targeted Review Evaluating Uncertainty in Single Technology Appraisal Submissions for Treatments Approved for Use Since the Introduction of the 'new' Cancer Drugs Fund
2019 · S. Critchlow, C. Lilley, et al. · Value in Health
PDF
Cost-effectiveness (CE) of avelumab vs standard care (SC) for the treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC)
2018 · M. Bharmal, A. Amin, et al. · Annals of Oncology
Works count: 17
Citation count: 43
H-index: 3
I10-index: 1
Year
Topic
Type